Lentiviral Vectors for Ocular Gene Therapy
Open accessThe DOI matches its Crossref record; 206 of the 208 references it cites were found in a registry or an index.
Abstract
This review offers the basics of lentiviral vector technologies, their advantages and pitfalls, and an overview of their use in the field of ophthalmology. First, the description of the global challenges encountered to develop safe and efficient lentiviral recombinant vectors for clinical application is provided. The risks and the measures taken to minimize secondary effects as well as new strategies using these vectors are also discussed. This review then focuses on lentiviral vectors specifically designed for ocular therapy and goes over preclinical and clinical studies describing their safety and efficacy. A therapeutic approach using lentiviral vector-mediated gene therapy is currently being developed for many ocular diseases, e.g., aged-related macular degeneration, retinopathy of prematurity, inherited retinal dystrophies (Leber congenital amaurosis type 2, Stargardt disease, Usher syndrome), glaucoma, and corneal fibrosis or engraftment rejection. In summary, this review shows how lentiviral vectors offer an interesting alternative for gene therapy in all ocular compartments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Entry and integration of HIV-1. Structural and enzymatic HIV-1 genes are presented in gray boxes, HIV-1 regulatory factors in green, HIV-1 accessory factors in blue, and LTR in yellow. Corresponding proteins are represented with the same color code in a schematic HIV-1 particle. The different processes, from binding to the cell membrane to the integration of the provirus DNA into the host genome, are depicted with viral protein required at each step. The timing of uncoating of the capsid (CA) and the role of CA is still unclear, as discussed in a recent review [11]. The Gag gene codes for matrix proteins (MA), capsid proteins (CA), and nucleocapsid protein (NC). The Pol gene encodes for the reverse transcriptase (RT), the integrase (IN), and the protease (PRO).](https://figures.cochat.ai/paper-figures/f17286d4d038409bb4bfc035d2358af9/lentiviral-vectors-for-ocular-gene-therapy-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, they carry risks for insertional mutagenesis and germline transmission and may elicit more inflammatory responses than AAVs.54,56,73”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 1×
“Then the SA, SD, cPPT, and RRE sequences are essential for the preparation and packaging of the transfer cassette into the recombinant viral particle and its import into the host cell nuclei [3,7].”
BackgroundProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184 · cited 1×
“New editing strategies, based on modified Cas9, allow for specifically replacing a cytosine or an adenine without inducing DNA double-strand break [156].”
BackgroundLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587 · cited 1×
“Indeed, since one of its first use in human clinics, gene therapy using retroviruses (Moloney retrovirus), despite showing at first an impressive efficiency, is unfortunately followed by a lethal risk of mutational insertion [23,24].”
BackgroundGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Indeed, since one of its first use in human clinics, gene therapy using retroviruses (Moloney retrovirus), despite showing at first an impressive efficiency, is unfortunately followed by a lethal risk of mutational insertion [23,24].”
BackgroundInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 1×
“This indicates that, unlike other retroviruses (gammaretroviral vectors [29]), LV insertional mutation event is a risk low enough to support the safety of LV for clinical use.”
BackgroundSelf-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis
Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H.-J., Benedict, W., & Bouck, N. P. (1999) · Science · doi:10.1126/science.285.5425.245 · Cited by 1,505 · cited 1×
“PEDF has both anti-angiogenic and neuroprotective actions [135,136].”
BackgroundNaldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276 · cited 1×
“Moreover, recombination at the post-transcriptional level, for example, between splicing sites of the viral RNA and the host RNAs, is another treatment to consider [19], even if it can sometimes be beneficial for the treatment [20].”
BackgroundDefective myosin VIIA gene responsible for Usher syndrome type IB
Well, D., Blanchard, S., Kaplan, J., Guilford, P., Gibson, F., Walsh, J., Mburu, P., Varela, A., Levilliers, J., Weston, M. D., et al. (1995) · Nature · doi:10.1038/374060a0 · Cited by 1,068 · cited 1×
“The shaker1 mouse model partially recapitulates the disease with congenital deafness appearance and vestibular dysfunction due to mutations in the Myo7a gene [159].”
Background
Cited by
Viral Vector-Based Gene Therapy
Li, X., Le, Y., Zhang, Z., Nian, X., Liu, B., & Yang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097736 · Cited by 200
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
The concept of gene therapy for glaucoma: the dream that has not come true yet
Sulak, R., Liu, X., & Smedowski, A. (2024) · Neural Regeneration Research · doi:10.4103/1673-5374.375319 · Cited by 40
“By affecting the outflow in Schlemm’s canal, it leads to the regulation of aqueous humor outflow (Arsenijevic et al., 2022).”
BackgroundGenome Editing, A Superior Therapy for Inherited Retinal Diseases
Yan, A. L., Du, S. W., & Palczewski, K. (2022) · Vision Research · doi:10.1016/j.visres.2023.108192 · Cited by 40
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics
Ou, L., Setegne, M. T., Elliot, J., Shen, F., & Dassama, L. M. K. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00595 · Cited by 33
Corneal fibrosis: From in vitro models to current and upcoming drug and gene medicines
Cubillo, L. T., Gürdal, M., & Zeugolis, D. I. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115317 · Cited by 33
Emerging Therapeutic Approaches and Genetic Insights in Stargardt Disease: A Comprehensive Review
Ghenciu, L. A., Hațegan, O. A., Stoicescu, E. R., Iacob, R., & Șișu, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168859 · Cited by 30
“Unlike other retroviruses, lentiviruses may penetrate non-dividing cells by importing their pre-integration complex into the nuclear compartment [10].”
BackgroundOcular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Banou, L., Sarrafpour, S., Teng, C. C., & Liu, J. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/hwid7537 · Cited by 30
Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases
Hansen, S., McClements, M. E., Corydon, T. J., & MacLaren, R. E. (2023) · Cells · doi:10.3390/cells12030440 · Cited by 25
“Lentiviral vectors also offer larger cargo capacity and are being developed for treatment of retinal disease [122] but currently show reduced transduction profiles compared to AAV vectors with transduction typically localized and limited to the RPE [123].”
BackgroundPatil, S., Kaipa, B. R., Ranshing, S., Sundaresan, Y., Millar, J. C., Nagarajan, B., Kiehlbauch, C. C., Zhang, Q., Jain, A., Searby, C. C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57286-6 · Cited by 27
Seeing the Future: A Review of Ocular Therapy
Whalen, M., Akula, M., McNamee, S. M., DeAngelis, M. M., & Haider, N. B. (2024) · Bioengineering · doi:10.3390/bioengineering11020179 · Cited by 21
“There are five lentiviral serogroups: human immunodeficient virus 1 (HIV-1), equine infectious anemia virus (EIAV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), and bovine immunodeficiency virus (BIV) [161].”
BackgroundGene Therapy in Diabetic Retinopathy and Diabetic Macular Edema: An Update
Odio-Herrera, M., Loaiza, G. O., & Wu, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093205 · Cited by 25
Ocular Gene Therapy: A Literature Review With Focus on Current Clinical Trials
Wasnik, V. B., & Thool, A. R. (2022) · Cureus · doi:10.7759/cureus.29533 · Cited by 22
“Used in Retinoblastoma [16] Most the clinical trials age-related macular degeneration, retinitis pigmentosa Stargardt disease Usher syndrome [17]”
MethodCorydon, T. J., & Bek, T. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101323 · Cited by 20
Looking to the Future of Viral Vectors in Ocular Gene Therapy: Clinical Review
Kharisova, C. B., Kitaeva, K. V., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., Ахметшин, Р. Ф., Bulgar, S. N., & Rizvanov, A. A. (2025) · Biomedicines · doi:10.3390/biomedicines13020365 · Cited by 19
Maurya, R., Vikal, A., Narang, R. K., Patel, P., & Kurmi, B. D. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109983 · Cited by 15
Shining light on CRISPR/Cas9 therapeutics for inherited retinal diseases
Geiger, A., Kennedy, J. G., Staker, L. G., Wensel, T. G., Casson, R. J., & Thomas, P. Q. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101376 · Cited by 11
Liquid foam improves potency and safety of gene therapy vectors
Fitzgerald, K., Stephan, S. B., Ma, N., Wu, Q. V., & Stephan, M. T. (2024) · Nature Communications · doi:10.1038/s41467-024-48753-9 · Cited by 8
“However, a rapidly growing number of trials are currently investigating LVs for in vivo gene therapy to treat monogenic diseases and chronic diseases, including neurological 17 , ophthalmological 18 , and metabolic disorders 19 .”
Barbieri, E., Mollica, G. N., Sripada, S. A., Shastry, S., Wu, Y., Minzoni, A., Smith, W. K., Wüstenhagen, E., Aldinger, A., Graalfs, H., et al. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70017 · Cited by 11
Retinal organoid and gene editing for basic and translational research
Cheng, Y.-M., Ma, C., Jin, K., & Jin, Z. (2023) · Vision Research · doi:10.1016/j.visres.2023.108273 · Cited by 8
Gene therapy for retinal diseases: From genetics to treatment
Khaparde, A., Mathias, G. P., Poornachandra, B., Thirumalesh, M. B., Shetty, R., & Ghosh, A. (2024) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2902_23 · Cited by 10
“[40] They are often used in clinical trials owing to their safety and efficacy.”
BackgroundToward lentiviral vectors for antiangiogenic ocular gene therapy
Askou, A. L., Jakobsen, T. S., & Corydon, T. J. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.007 · Cited by 8
“However, advances in LV technology convincingly suggest the use of LVs for clinical application.(7) Importantly, several features make LVs favorable compared with AAVs: They provide stable expression due to genome integration, and the larger packaging capacity ( 9 kb) compared with AAVs ( 4.”
BackgroundInfluentialPal, S., & Mandal, S. (2025) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2025.1004111 · Cited by 9
Diress, M., Ionescu, C. M., Foster, T., Lim, P., Sen, L. Y., Kovačević, B., Wagle, S. R., Mooranian, A., & Al‐Salami, H. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107172 · Cited by 5
Nanoparticle-Based gene therapy strategies in retinal delivery
Foster, T., Lim, P., Wagle, S. R., Ionescu, C. M., Kovačević, B., McLenachan, S., Carvalho, L. S., Brunet, A. A., Mooranian, A., & Al‐Salami, H. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2024.2433563 · Cited by 6
“…not considered viable gene delivery systems in the eye [103]. lentiviral vectors are an emerging gene delivery technique for ocular gene therapies [115]. lentiviruses are integrating retroviruses that contain two sense RNA strands [104]. lentiviral vectors are known to have several advantages…”
Gene therapy in neovascular age related macular degeneration: an update
Quesada, E., Vázquez, S. R., Campos, X., & Wu, L. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-06837-2 · Cited by 5
“Members include the human immunodeficient virus 1 (HIV-1), the equine infectious anemia virus (EIAV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV) and the bovine immunodeficiency virus (BIV) [71].”
Adak, S., Jadhav, V. S., & Khatri, D. K. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01925-6 · Cited by 11
“The integration of lentiviral vectors into the host genome enables the stable and sustained generation of therapeutic genes [202].”
Butt, F. R., Dhivagaran, T., Li, B., Ashamalla, M., Tao, B. K.-L., Balas, M., Pereira, A., Yan, P., & Arjmand, P. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120619 · Cited by 9
“Lentiviral (LV) vectors offer an alternative gene delivery system with a larger transgene capacity (~8 kb) and the ability to integrate into the host genome, enabling stable long-term transgene expression [16,18].”
AAV-based gene therapies for neovascular AMD
Kim, T. H., Kwon, C. Y., Song, J. Y., & Yoo, H. C. (2026) · Gene Therapy · doi:10.1038/s41434-026-00595-4 · Cited by 7
“However, because the eye and central nervous system (CNS) are immune-privileged sites, localized in vivo application of lentiviral vectors is feasible, although vector leakage into the bloodstream can increase immunogenicity [46, 47].”
Gene Therapy Strategies for the Treatment of Bestrophinopathies
Hansen, S., McClements, M. E., Cehajic‐Kapetanovic, J., Corydon, T. J., & MacLaren, R. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199421 · Cited by 4
Cai, S., Liang, X. B., Wu, H., Li, X., & Pu, Q. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101421 · Cited by 4
Hydrogel-Based Formulations for Drug Delivery to the Posterior Segment of the Eye
Bahmanpour, A., Mollazadeh-Bajestani, M., Ghaffari, M., Moztarzadeh, F., & Sepahvandi, A. (2023) · Annals of Biomedical Science and Engineering · doi:10.29328/journal.abse.1001024 · Cited by 3
“Various vectors, including modi ied viruses and non-viral vectors, are used for gene delivery [31].”
BackgroundDevelopment of an RNA virus-based episomal vector with artificial aptazyme for gene silencing
Komorizono, R., Yoshizumi, S., & Tomonaga, K. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-024-13327-8 · Cited by 3
Development of HIV-1 vectors pseudotyped with envelope proteins of other retroviruses
Stitz, J. (2024) · Virology · doi:10.1016/j.virol.2024.110300 · Cited by 4
Wang, M., Zheng, H., Ding, H., Liu, S., Wang, Z., Zheng, L., & Sui, Z. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c01862 · Cited by 2
Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma
Azani, A., Ghassemifar, V., Mehrdad, Z., Saberivand, M., Pour, A. B., Tahmasebi, S., Gharedaghi, H., Sharafi, M., Foroozand, H., Meigoli, M. S. S., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70425 · Cited by 2
“Lentiviruses are more capable of carrying transmissible genes than AAV, and by removing genes of the vector itself, it is possible to reduce the inflammatory response [167].”
Zaki, H. F., Bishri, J., Muqtadir, M. A., & Abu-Zaid, A. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.111119 · Cited by 2
Non-infectious particle removal in lentiviral vector purification: A path to higher quality
Fernandes, R. P., Ruiz, A. B., Bezemer, S., Detmers, F. J. M., Hermans, P., Faria, T. Q., & Peixoto, C. (2026) · Separation and Purification Technology · doi:10.1016/j.seppur.2026.138432 · Cited by 1
Ocular Gene Therapy: Literature Review
Naser, M., Nasr, M., & Shehata, L. H. (2023) · International Journal of Progressive Sciences and Technologies · doi:10.52155/ijpsat.v40.2.5623 · Cited by 1
Current Updates, Recent Trends and Future Directions of Gene Therapy on Various Eye Disorders
Rehman, S. U., Javed, U., Saleem, A., Saleem, M. H., Hameed, U., Muzaffar, K., Raza, T., Ijaz, R., & Ali, F. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i1.524 · Cited by 1
Updates on Gene Therapy for Neovascular Age-related Macular Degeneration: A Review
Sharma, A., & Kumar, N. (2024) · EyeQuest · doi:10.4103/equest.equest_25_24
Shaban, A. H., El‐Gebaly, A. M., Sayed, A. O., Abdullatef, A. M., Ahmed, A. M., El-Beheady, A., Mostafa, D. M. M., Eid, E. M. A., El-Kady, H. A., Masoud, H. H., et al. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106660
Biomaterials in Retinal Regeneration
Hicks, E. A., Monteiro, A., Tran, N., Sheardown, L., & Sheardown, H. D. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781839169779-00256
Stargardt Disease ( ABCA4 -Associated Retinopathies)
Utz, V. M., & Traboulsi, E. I. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197659403.003.0037
Bevc, L., Rijavec, A. P., Novak, V., Šuleski, S. P., Koshmak, I. P., Leskovec, M., Jug, H., & Štrancar, A. (2026) · Electrophoresis · doi:10.1002/elps.70159
Wu, Y., Minzoni, A., Gangadhar, A., Smith, W. K., Barbieri, E., Ismail, I., Remmler, L. A., Daniele, M. A.-A., & Menegatti, S. (2026) · Journal of Chromatography A · doi:10.1016/j.chroma.2026.467470
Retinitis Pigmentosa: A Review of Its Pathogenesis and Emerging Molecular and Cellular Therapies
Tuli, N., Baeshen, M., Echbicheb, M., Kulbay, M., Ayalon, A., Ali, S. K., & Qian, C. X. (2026) · Vision · doi:10.3390/vision10040083
“Despite their promise, concerns remain, including the risk of producing replication-competent or pathogenic LVs, immunogenicity, and insertional mutagenesis [309,329].”
Metadata
- Authors
- Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C.
- Affiliations
- Unit Retinal Degeneration and Regeneration, Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, 1004 Lausanne, Switzerland
- Fondation Asile des Aveugles (CH)
- Hôpital Ophtalmique Jules-Gonin (CH)
- Corresponding author
- Kostic, Corinne
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-07-31
- Volume
- 14
- Issue
- 8
- Pages
- 1605
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9414879
- OpenAlex
- W4289203946
- Cited by
- 47
- References
- 208
- Citations by year
- 2026: 6 · 2025: 19 · 2024: 12 · 2023: 8 · 2022: 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by)
- IRIS (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fondation Asile des Aveugles (.)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- lentiviral vectors, ocular gene therapy, age-related macular degeneration, retinopathy of prematurity, inherited retinal disease, Stargardt disease, Usher syndrome, glaucoma, corneal fibrosis, preclinical and clinical studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.